ADJUBIL - A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJUvant situation for BILiary tract cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511847-24-00

Acronym

ADJUBIL

Enrollment

Registered

2024-09-20

Start date

2022-05-23

Completion date

2025-02-20

Last updated

2025-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary tract cancer

Brief summary

Recurrence free survival at 12 months (RFS@12)

Detailed description

Recurrence free survival (RFS), Overall survival (OS), Safety (AEs, impact of liver function, use of subsequent therapies), QoL, Exploratory endpoints: Collection of tissue and blood samples for future evaluation of predictive biomarkers for RFS and OS.

Interventions

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGCAPECITABINE

DRUGTREMELIMUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Recurrence free survival at 12 months (RFS@12)	—

Secondary

Measure	Time frame
Recurrence free survival (RFS), Overall survival (OS), Safety (AEs, impact of liver function, use of subsequent therapies), QoL, Exploratory endpoints: Collection of tissue and blood samples for future evaluation of predictive biomarkers for RFS and OS.	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026